ArticleJBMR plus2026
Burosumab as bridging therapy in autosomal dominant hypophosphatemic rickets with femoral fracture nonunion and iron deficiency.
Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autosomal dominant hypophosphatemic rickets (ADHR) is a rare genetic disorder, characterized by fibroblast growth factor 23 (FGF23)-mediated renal phosphate wasting and impaired bone mineralization. Iron deficiency in ADHR increases FGF23 production and can worsen hypophosphatemia. Evidence to guide optimal management in severe adult cases remains limited. We report the use of burosumab as bridging therapy in a 19-yr-old woman with genetically confirmed ADHR (FGF23 p.Arg176Trp), severe osteomalacia, iron-deficiency anemia, and a low-energy femoral diaphyseal fracture complicated by nonunion despite conventional therapy. Treatment with burosumab resulted in rapid clinical improvement, with marked reduction in musculoskeletal pain and stiffness, and restoration of independent ambulation within four months. BMD increased substantially (+11.7% at the LS and +14.2% at the total hip at 5 mo; +63.8% and +55.5% from baseline at approximately 11 mo, respectively), while trabecular bone score remained within the normal range, a pattern consistent with improved mineralization and preserved trabecular texture. Serum phosphate increased but did not consistently normalize at trough, prompting dose escalation. At 8 mo, the burosumab dose was increased to 50 mg (1.25 mg/kg) due to persistent hypophosphatemia; with concurrent oral iron replacement, transient hyperphosphatemia (1.61 mmol/L) occurred and was managed by delaying the next dose by 14 d and reducing the dose back to 1 mg/kg. The patient also underwent additional surgical intervention, which may have contributed to the overall outcome; radiographic callus formation was evident 5 mo post-surgery. To our knowledge, this is the first full-length report describing burosumab use in genetically confirmed ADHR with longitudinal biochemical and densitometric follow-up, and it highlights the importance of careful monitoring of phosphate and iron indices when combining therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.